Investment analysts at JPMorgan Chase & Co. started coverage on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research note issued on Monday, The Fly reports. The firm set a “neutral” rating on the stock.
DCPH has been the topic of several other reports. Zacks Investment Research downgraded shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 29th. SVB Leerink decreased their price objective on shares of Deciphera Pharmaceuticals from $55.00 to $54.00 and set a “market perform” rating on the stock in a research report on Wednesday, August 5th. Guggenheim restated a “buy” rating and set a $70.00 price objective on shares of Deciphera Pharmaceuticals in a research report on Friday, June 12th. Barclays restated a “buy” rating and set a $85.00 price objective (up from $80.00) on shares of Deciphera Pharmaceuticals in a research report on Monday, May 18th. Finally, BidaskClub downgraded shares of Deciphera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, August 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $70.86.
Shares of Deciphera Pharmaceuticals stock opened at $51.49 on Monday. The company’s fifty day simple moving average is $46.03 and its 200-day simple moving average is $49.93. The stock has a market capitalization of $2.90 billion, a PE ratio of -10.00 and a beta of 1.84. Deciphera Pharmaceuticals has a 1-year low of $31.37 and a 1-year high of $71.11. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.33 and a quick ratio of 12.30.
In other Deciphera Pharmaceuticals news, Director James Arthur Bristol sold 23,541 shares of Deciphera Pharmaceuticals stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $54.99, for a total value of $1,294,519.59. Following the sale, the director now directly owns 16,324 shares in the company, valued at approximately $897,656.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Thomas Patrick Kelly sold 3,000 shares of Deciphera Pharmaceuticals stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $47.71, for a total transaction of $143,130.00. Following the completion of the transaction, the chief financial officer now directly owns 13,040 shares of the company’s stock, valued at $622,138.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 108,330 shares of company stock worth $5,966,578. 3.81% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of DCPH. Vanguard Group Inc. grew its stake in shares of Deciphera Pharmaceuticals by 41.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,549,561 shares of the company’s stock worth $211,980,000 after buying an additional 1,034,589 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Deciphera Pharmaceuticals by 36.4% in the 1st quarter. Franklin Resources Inc. now owns 3,237,383 shares of the company’s stock valued at $133,283,000 after acquiring an additional 864,661 shares during the last quarter. Redmile Group LLC boosted its holdings in shares of Deciphera Pharmaceuticals by 8.6% in the 1st quarter. Redmile Group LLC now owns 5,116,263 shares of the company’s stock valued at $210,637,000 after acquiring an additional 406,765 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its holdings in shares of Deciphera Pharmaceuticals by 1,797,864.3% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 251,715 shares of the company’s stock valued at $15,033,000 after acquiring an additional 251,701 shares during the last quarter. Finally, Eventide Asset Management LLC purchased a new stake in shares of Deciphera Pharmaceuticals in the 1st quarter valued at $10,004,000. 74.63% of the stock is owned by institutional investors and hedge funds.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.